Moderna, Inc. $MRNA Shares Bought by Theleme Partners LLP

Theleme Partners LLP lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,068,810 shares of the company’s stock after purchasing an additional 200,000 shares during the quarter. Moderna comprises about 13.3% of Theleme Partners LLP’s investment portfolio, making the stock its 3rd biggest position. Theleme Partners LLP’s holdings in Moderna were worth $208,417,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Rothschild Investment LLC increased its stake in Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after purchasing an additional 446 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new stake in Moderna in the 2nd quarter worth about $26,000. MUFG Securities EMEA plc purchased a new stake in Moderna in the 2nd quarter valued at about $28,000. Ameriflex Group Inc. grew its holdings in Moderna by 3,775.0% in the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after buying an additional 1,208 shares during the period. Finally, Assetmark Inc. increased its stake in shares of Moderna by 137.7% during the 2nd quarter. Assetmark Inc. now owns 1,298 shares of the company’s stock valued at $36,000 after acquiring an additional 752 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 1.8%

Shares of NASDAQ:MRNA opened at $55.97 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $59.55. The stock has a market capitalization of $22.10 billion, a P/E ratio of -7.70 and a beta of 1.29. The stock has a 50-day simple moving average of $44.64 and a 200-day simple moving average of $32.86.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, beating the consensus estimate of ($2.79) by $0.68. The firm had revenue of $678.00 million for the quarter, compared to analyst estimates of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. Moderna’s revenue for the quarter was down 33.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.91) earnings per share. Equities analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Insider Activity

In other news, President Stephen Hoge sold 160,009 shares of the stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total value of $7,814,839.56. Following the completion of the sale, the president owned 1,457,427 shares of the company’s stock, valued at $71,180,734.68. This represents a 9.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MRNA. Leerink Partners reiterated an “underperform” rating on shares of Moderna in a report on Friday, January 30th. Wolfe Research reaffirmed an “underperform” rating and set a $17.00 price target on shares of Moderna in a research report on Thursday, November 20th. Piper Sandler increased their price target on shares of Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, February 23rd. BMO Capital Markets upgraded shares of Moderna from a “market perform” rating to a “buy” rating in a report on Monday, January 12th. Finally, Citigroup reissued a “neutral” rating on shares of Moderna in a research note on Monday, February 16th. Two research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average price target of $32.33.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.